Which has better valuation and earnings, DCGO or XGN?

Exagen has lower revenue, but higher earnings than DocGo. Exagen is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $322.20M 0.18 -$182.40M -$1.91 N/A Exagen $66.57M 1.60 -$19.95M -$0.89 N/A

Is DCGO or XGN more profitable?

Exagen has a net margin of -29.49% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -62.23% -44.09% -29.14% Exagen -29.49% -94.37% -28.96%

Do analysts rate DCGO or BNR?

DocGo currently has a consensus price target of $2.38, indicating a potential upside of 303.98%. Given DocGo's stronger consensus rating and higher possible upside, equities research analysts plainly believe DocGo is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DocGo 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor DCGO or BNR?

In the previous week, Burning Rock Biotech had 14 more articles in the media than DocGo. MarketBeat recorded 16 mentions for Burning Rock Biotech and 2 mentions for DocGo. Burning Rock Biotech's average media sentiment score of 1.01 beat DocGo's score of 0.40 indicating that Burning Rock Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DocGo 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Burning Rock Biotech 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, PIII or DCGO?

P3 Health Partners has higher revenue and earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio P3 Health Partners $1.46B 0.05 -$147.95M -$38.60 N/A DocGo $322.20M 0.18 -$182.40M -$1.91 N/A

Is PIII or DCGO more profitable?

P3 Health Partners has a net margin of -8.57% compared to DocGo's net margin of -62.23%. P3 Health Partners' return on equity of 0.00% beat DocGo's return on equity. Company Net Margins Return on Equity Return on Assets P3 Health Partners -8.57% N/A -19.99% DocGo -62.23% -44.09% -29.14%

Does the media prefer PIII or DCGO?

In the previous week, DocGo had 1 more articles in the media than P3 Health Partners. MarketBeat recorded 2 mentions for DocGo and 1 mentions for P3 Health Partners. DocGo's average media sentiment score of 0.40 beat P3 Health Partners' score of 0.00 indicating that DocGo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment P3 Health Partners 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DocGo 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SERA or DCGO more profitable?

DocGo has a net margin of -62.23% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat DocGo's return on equity. Company Net Margins Return on Equity Return on Assets Sera Prognostics -56,385.97% -41.02% -30.95% DocGo -62.23% -44.09% -29.14%

Does the media prefer SERA or DCGO?

In the previous week, Sera Prognostics and Sera Prognostics both had 2 articles in the media. DocGo's average media sentiment score of 0.40 beat Sera Prognostics' score of 0.00 indicating that DocGo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sera Prognostics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DocGo 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

DocGo (DCGO) Competitors

$0.59 +0.03 (+5.81%)

Closing price 07/6/2026 04:00 PM Eastern

Extended Trading

$0.58 -0.01 (-1.51%)

As of 04:00 AM Eastern

Compare

DCGO vs. XGN, PARK, BNR, PIII, and SERA

Should you buy DocGo stock or one of its competitors? MarketBeat compares DocGo with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DocGo include Exagen (XGN), Park Dental Partners (PARK), Burning Rock Biotech (BNR), P3 Health Partners (PIII), and Sera Prognostics (SERA). These companies are all part of the "healthcare" industry.

How does DocGo compare to Exagen?

DocGo (NASDAQ:DCGO) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

56.4% of DocGo shares are owned by institutional investors. Comparatively, 75.3% of Exagen shares are owned by institutional investors. 3.8% of DocGo shares are owned by insiders. Comparatively, 10.4% of Exagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

DocGo presently has a consensus target price of $2.38, suggesting a potential upside of 303.98%. Exagen has a consensus target price of $9.11, suggesting a potential upside of 107.07%. Given DocGo's higher possible upside, equities research analysts plainly believe DocGo is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

In the previous week, DocGo had 2 more articles in the media than Exagen. MarketBeat recorded 2 mentions for DocGo and 0 mentions for Exagen. DocGo's average media sentiment score of 0.40 beat Exagen's score of 0.00 indicating that DocGo is being referred to more favorably in the media.

Company	Overall Sentiment
DocGo	Neutral
Exagen	Neutral

DocGo has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market. Comparatively, Exagen has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market.

Exagen has lower revenue, but higher earnings than DocGo. Exagen is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.18	-$182.40M	-$1.91	N/A
Exagen	$66.57M	1.60	-$19.95M	-$0.89	N/A

Exagen has a net margin of -29.49% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-62.23%	-44.09%	-29.14%
Exagen	-29.49%	-94.37%	-28.96%

Summary

Exagen beats DocGo on 11 of the 16 factors compared between the two stocks.

How does DocGo compare to Park Dental Partners?

DocGo (NASDAQ:DCGO) and Park Dental Partners (NASDAQ:PARK) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

56.4% of DocGo shares are held by institutional investors. 3.8% of DocGo shares are held by company insiders. Comparatively, 10.6% of Park Dental Partners shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Park Dental Partners has a net margin of 0.00% compared to DocGo's net margin of -62.23%. Park Dental Partners' return on equity of 0.00% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-62.23%	-44.09%	-29.14%
Park Dental Partners	N/A	N/A	N/A

DocGo currently has a consensus price target of $2.38, suggesting a potential upside of 303.98%. Park Dental Partners has a consensus price target of $21.75, suggesting a potential upside of 4.57%. Given DocGo's higher probable upside, equities research analysts plainly believe DocGo is more favorable than Park Dental Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75

Park Dental Partners has lower revenue, but higher earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than Park Dental Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.18	-$182.40M	-$1.91	N/A
Park Dental Partners	$244.49M	0.38	-$360K	$0.74	28.11

In the previous week, DocGo had 2 more articles in the media than Park Dental Partners. MarketBeat recorded 2 mentions for DocGo and 0 mentions for Park Dental Partners. DocGo's average media sentiment score of 0.40 beat Park Dental Partners' score of 0.00 indicating that DocGo is being referred to more favorably in the media.

Company	Overall Sentiment
DocGo	Neutral
Park Dental Partners	Neutral

Summary

Park Dental Partners beats DocGo on 9 of the 15 factors compared between the two stocks.

How does DocGo compare to Burning Rock Biotech?

DocGo (NASDAQ:DCGO) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Burning Rock Biotech has lower revenue, but higher earnings than DocGo. Burning Rock Biotech is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.18	-$182.40M	-$1.91	N/A
Burning Rock Biotech	$77.16M	1.41	-$7.92M	-$0.82	N/A

In the previous week, Burning Rock Biotech had 14 more articles in the media than DocGo. MarketBeat recorded 16 mentions for Burning Rock Biotech and 2 mentions for DocGo. Burning Rock Biotech's average media sentiment score of 1.01 beat DocGo's score of 0.40 indicating that Burning Rock Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DocGo	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Burning Rock Biotech	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DocGo currently has a consensus price target of $2.38, indicating a potential upside of 303.98%. Given DocGo's stronger consensus rating and higher possible upside, equities research analysts plainly believe DocGo is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Burning Rock Biotech has a net margin of -11.57% compared to DocGo's net margin of -62.23%. Burning Rock Biotech's return on equity of -10.98% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-62.23%	-44.09%	-29.14%
Burning Rock Biotech	-11.57%	-10.98%	-7.33%

56.4% of DocGo shares are owned by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are owned by institutional investors. 3.8% of DocGo shares are owned by company insiders. Comparatively, 30.3% of Burning Rock Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

DocGo has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market.

Summary

Burning Rock Biotech beats DocGo on 10 of the 15 factors compared between the two stocks.

How does DocGo compare to P3 Health Partners?

P3 Health Partners (NASDAQ:PIII) and DocGo (NASDAQ:DCGO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

In the previous week, DocGo had 1 more articles in the media than P3 Health Partners. MarketBeat recorded 2 mentions for DocGo and 1 mentions for P3 Health Partners. DocGo's average media sentiment score of 0.40 beat P3 Health Partners' score of 0.00 indicating that DocGo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
P3 Health Partners	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DocGo	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

P3 Health Partners has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market. Comparatively, DocGo has a beta of 1.02, indicating that its stock price is 2% more volatile than the broader market.

7.8% of P3 Health Partners shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 10.9% of P3 Health Partners shares are owned by insiders. Comparatively, 3.8% of DocGo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

P3 Health Partners has higher revenue and earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.46B	0.05	-$147.95M	-$38.60	N/A
DocGo	$322.20M	0.18	-$182.40M	-$1.91	N/A

P3 Health Partners has a net margin of -8.57% compared to DocGo's net margin of -62.23%. P3 Health Partners' return on equity of 0.00% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-8.57%	N/A	-19.99%
DocGo	-62.23%	-44.09%	-29.14%

P3 Health Partners presently has a consensus price target of $14.00, suggesting a potential upside of 36.05%. DocGo has a consensus price target of $2.38, suggesting a potential upside of 303.98%. Given DocGo's stronger consensus rating and higher probable upside, analysts plainly believe DocGo is more favorable than P3 Health Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

DocGo beats P3 Health Partners on 8 of the 15 factors compared between the two stocks.

How does DocGo compare to Sera Prognostics?

Sera Prognostics (NASDAQ:SERA) and DocGo (NASDAQ:DCGO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 11.3% of Sera Prognostics shares are owned by company insiders. Comparatively, 3.8% of DocGo shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Sera Prognostics and Sera Prognostics both had 2 articles in the media. DocGo's average media sentiment score of 0.40 beat Sera Prognostics' score of 0.00 indicating that DocGo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sera Prognostics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DocGo	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sera Prognostics has higher earnings, but lower revenue than DocGo. Sera Prognostics is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	1,023.06	-$31.93M	-$0.65	N/A
DocGo	$322.20M	0.18	-$182.40M	-$1.91	N/A

Sera Prognostics presently has a consensus price target of $5.50, suggesting a potential upside of 163.16%. DocGo has a consensus price target of $2.38, suggesting a potential upside of 303.98%. Given DocGo's higher possible upside, analysts plainly believe DocGo is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Sera Prognostics has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, DocGo has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market.

DocGo has a net margin of -62.23% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-56,385.97%	-41.02%	-30.95%
DocGo	-62.23%	-44.09%	-29.14%

Summary

DocGo beats Sera Prognostics on 8 of the 15 factors compared between the two stocks.

Get DocGo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCGO vs. The Competition

Export

Metric	DocGo	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$54.87M	$9.43B	$6.92B	$12.59B
Dividend Yield	N/A	1.62%	2.66%	6.52%
P/E Ratio	N/A	27.37	27.35	24.81
Price / Sales	0.18	25.92	507.73	89.92
Price / Cash	10.04	15.44	29.65	49.23
Price / Book	0.46	6.26	11.06	6.50
Net Income	-$182.40M	$177.20M	$3.57B	$336.03M
7 Day Performance	13.91%	6.20%	2.56%	2.68%
1 Month Performance	5.13%	13.03%	7.39%	5.50%
1 Year Performance	-61.32%	15.06%	34.13%	25.01%

DocGo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCGO DocGo	2.964 of 5 stars	$0.59 +5.8%	$2.38 +304.0%	-62.9%	$54.87M	$322.20M	N/A	3,568
XGN Exagen	3.628 of 5 stars	$4.58 -1.3%	$9.11 +98.9%	-34.7%	$110.65M	$66.57M	N/A	220	Positive News
PARK Park Dental Partners	2.0194 of 5 stars	$19.49 +6.8%	$21.75 +11.6%	N/A	$88.00M	$248.15M	N/A	1,208	Positive News
BNR Burning Rock Biotech	1.8212 of 5 stars	$8.23 +3.5%	N/A	+206.1%	$86.57M	$77.16M	N/A	1,390	Positive News
PIII P3 Health Partners	2.4293 of 5 stars	$11.31 +5.9%	$14.00 +23.8%	+61.7%	$81.88M	$1.46B	N/A	500	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCGO) was last updated on 7/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DocGo (DCGO) Competitors

DCGO vs. XGN, PARK, BNR, PIII, and SERA

How does DocGo compare to Exagen?

Summary

How does DocGo compare to Park Dental Partners?

Summary

How does DocGo compare to Burning Rock Biotech?

Summary

How does DocGo compare to P3 Health Partners?

Summary

How does DocGo compare to Sera Prognostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCGO vs. The Competition

DocGo Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DocGo (DCGO) Competitors

DCGO vs. XGN, PARK, BNR, PIII, and SERA

How does DocGo compare to Exagen?

Do institutionals & insiders hold more shares of DCGO or XGN?

Do analysts prefer DCGO or XGN?

Does the media refer more to DCGO or XGN?

Which has more volatility and risk, DCGO or XGN?

Which has better valuation and earnings, DCGO or XGN?

Is DCGO or XGN more profitable?

Summary

How does DocGo compare to Park Dental Partners?

Do insiders & institutionals hold more shares of DCGO or PARK?

Is DCGO or PARK more profitable?

Do analysts recommend DCGO or PARK?

Which has better earnings and valuation, DCGO or PARK?

Does the media favor DCGO or PARK?

Summary

How does DocGo compare to Burning Rock Biotech?

Which has higher valuation and earnings, DCGO or BNR?

Does the media favor DCGO or BNR?

Do analysts rate DCGO or BNR?

Is DCGO or BNR more profitable?

Do institutionals & insiders believe in DCGO or BNR?

Which has more volatility and risk, DCGO or BNR?

Summary

How does DocGo compare to P3 Health Partners?

Does the media prefer PIII or DCGO?

Which has more risk and volatility, PIII or DCGO?

Do insiders and institutionals hold more shares of PIII or DCGO?

Which has preferable valuation & earnings, PIII or DCGO?

Is PIII or DCGO more profitable?

Do analysts rate PIII or DCGO?

Summary

How does DocGo compare to Sera Prognostics?

Do insiders & institutionals hold more shares of SERA or DCGO?

Does the media prefer SERA or DCGO?

Which has preferable valuation and earnings, SERA or DCGO?

Do analysts prefer SERA or DCGO?

Which has more volatility & risk, SERA or DCGO?

Is SERA or DCGO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCGO vs. The Competition

DocGo Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools